Covered stent placement for treatment of coarctation of the aorta: immediate and long-term results.

Jan Stassen MD^a, Pieter De Meester MD, PhD^{a,b}, Els Troost MD^a, Leen Roggen NSc^a, Philip Moons Nsc, PhD^{c,d,e}, Marc Gewillig MD, PhD^{b,f}, Alexander Van De Bruaene MD, PhD^{a,b}, Werner Budts MD, PhD^{a,b}

^a Clinical Department of cardiovascular diseases, University Hospitals Leuven, ^b Department of cardiovascular Sciences, KU Leuven, ^c Department of Public Health and Primary Care, KU Leuven, ^d Institute of Health and Care Science, University of Gothenburg, Sweden, ^e Department of Pediatrics and Child Health, University of Cape Town, South Africa and ^f Clinical Department of Pediatric Cardiology, University Hospitals Leuven, Belgium

Total word count: 4296

Running title: Coarctation and covered stenting

Financial disclosures: No.

Conflict of interest: MG is proctor for Numed; WB is proctor for Occlutech and Abbott.

Address for correspondence:

Werner Budts, MD, PhD

Congenital and Structural Cardiology

University Hospitals Leuven

Herestraat 49,

B-3000 Leuven

Tel: 003216344369

Fax: 003216344240

Email: werner.budts@uzleuven.be

Abstract

Objectives: This study aimed to describe the safety and efficacy of covered stents in patients with coarctation of aorta (CoA) for immediate and long-term follow-up.

Background: Covered stents are increasingly being used in (re)CoA, mainly to reduce the risk of aortic wall injuries (AWI). However, limited data are available on intermediate and long-term outcome.

Methods: In eighty-nine patients (67.4% male) with a mean age of 23.9 ± 15.8 (min max range 5.1 – 71.6) years were 102 covered stents implanted (January 2003 – December 2017). Short-term pre/post-implant hemodynamics and angiographic data were reported. Changes in blood pressure, the use of antihypertensive drugs and complications were recorded during follow-up.

Results: The procedural success rate was 100%. The mean invasive ascending-to-descending aorta systolic gradient under general anesthesia decreased from 25 ± 16 mmHg to 4 ± 7 mmHg ($p < 0.001$). After a mean follow-up time of 6.6 ± 3.7 years, there was a persistent improvement of the mean systolic blood pressure gradient between right arm and leg (-7 ± 18 vs 38 ± 24 mmHg; $p < 0.001$). A larger proportion of patients required antihypertensive medication (33.7% vs 50.0%, $p = 0.017$) and needed ≥ 2 drugs (20.2% vs 27.4%, $p = 0.066$) to control blood pressure. Long-term adverse events were found in 4.5% of patients (covered stent fracture ($n=3$), aneurysm formation ($n=2$)).

Conclusions: Covered stent implantation for CoA is highly successful, safe and results in a persistent hemodynamic improvement in the immediate and long-term outcome. Lifelong follow-up with additional antihypertensive drug treatment is mandatory to maintain favorable hemodynamic results after stenting.

Keywords

Coarctation, stent, congenital, covered

Condensed abstract

Long-term follow-up data on covered stents in patients with coarctation of the aorta are scarce. A cohort of 89 patients was reviewed. The procedural implantation success rate was 100%. The invasive gradient decreased from 25 ± 16 mmHg to 4 ± 7 mmHg ($p<0.001$). After follow-up of 6.6 ± 3.7 years, there was a persistent improvement of the clinical systolic blood pressure gradient (-7 ± 18 vs 38 ± 24 mmHg; $p<0.001$). However, a larger proportion of patients required antihypertensive medication (33.7% vs 50.0%, $p=0.017$). Covered stent implantation results in favorable hemodynamic effects, but lifelong follow-up with additional antihypertensive drug treatment is mandatory to maintain these results.

Abbreviations

AWI: aortic wall injuries

BP: blood pressure

CCP: cover Cheatham Platinum

CoA: coarctation of the aorta

IQR: interquartile range

SBP: systolic blood pressure

Introduction

Coarctation of the aorta (CoA) is a congenital cardiovascular malformation, characterized by a restriction of the lumen of the thoracic aorta. This restriction is often just distal to the left subclavian artery and described as the adult type of CoA, whereas other patients have a more diffuse hypoplastic aortic arch or the combination of both. It occurs in approximately 4 of 10.000 live births and comprises 5% to 8% of congenital heart disease¹. Mostly, CoA is detected in childhood and repaired surgically or by endovascular therapy. Occasionally it is diagnosed in adolescence or adulthood by investigations done for systemic hypertension. Exact numbers of late diagnosis of CoA are not reported in literature, but in a high-volume center of adult congenital heart disease, it ranges between 2 – 4 diagnoses per year (data from the University Hospitals Leuven). The natural history of CoA carries a poor prognosis due to complications such as left ventricular failure, intracranial hemorrhage, aortic rupture or dissection, premature coronary artery disease and sudden death²⁻⁶.

Smaller and younger infants are typically treated surgically but remain at risk for recurrent obstruction with up to 10% requiring further intervention during adulthood^{5,7}.

In older children and adults, the preferred treatment method depends on the individual anatomy and nature of the lesion, but endovascular therapy with either balloon angioplasty or stent implantation is commonly preferred over surgery⁸⁻¹⁴. Although balloon angioplasty results in excellent acute hemodynamics, it is associated with a high rate of aortic wall injury and recurrent obstruction¹⁴⁻¹⁶. Because of these concerns, stent implantation is usually favored to avoid overdilation or the elastic recoil of the aorta. Bare stent implantation has become a worthy alternative to surgery and balloon angioplasty and seems to lead to better results and fewer complications^{10,11,15-18}. However, although interventions with bare stent

implantation seem efficient and generally safe, major complications such as local aneurysm formation, aortic rupture, dissection and even death may occur ^{12,13}. To prevent these aortic wall injuries (AWI) during the stent procedure, covered stents are increasingly used and their safety and efficacy for immediate and intermediate follow-up have been demonstrated ¹⁹⁻²³. However, long-term results remain limited. Therefore, we aimed to investigate the impact and safety of covered stent placement for treatment of (re)CoA during a longer follow-up period.

Methods

Study design and patients

This retrospective study assessed 89 patients with CoA who were treated with 102 covered stents in 93 procedures from 2003 to 2017 at the University Hospitals Leuven, Belgium.

All patients with a covered stent implantation for a native CoA or reCoA after surgical or transcatheter repair were included. Indications for stenting included hypertensive patients with an increased non-invasive gradient between upper and lower limbs confirmed with invasive measurement (peak-to-peak ≥ 20 mmHg) and it was considered in hypertensive patients with $\geq 50\%$ narrowing of the aorta relative to the aortic diameter at the diaphragm, even if the invasive peak-to-peak gradient was < 20 mmHg and in normotensive patients with an increased non-invasive gradient confirmed with invasive measurement (peak-to-peak ≥ 20 mmHg), when technically feasible²⁴. Hypertension in children was defined as a systolic arterial pressure above the 95th percentile for their age and for adults the definition was in accordance to the ESC guidelines for the management of arterial hypertension²⁵. Patients with associated congenital defects such as bicuspid or asymmetric tricuspid aortic valve and ventricular septum defect were included in the study, but patients with an associated more complex congenital cardiac anomaly were excluded. Hypoplastic arches were included. Transverse arch hypoplasia was defined as an arch index of less than 0.5 in which the arch index is the ratio of the transverse aortic arch diameter to the ascending and/or descending aorta diameter²⁶. Clinical data, including age, sex, type and location of the coarctation and previous interventions were recorded at inclusion. The study was performed in accordance with the local ethics committee guidelines, University Hospitals

Leuven, Belgium (S61175). Because of the retrospective design, informed consent was waived.

Materials and stenting procedure

All patients underwent a diagnostic catheterization for invasive pressure gradient measurements, subsequently followed by covered stent implantation. The technique of stent implantation has been described before²⁷. In summary, the aortic lumen at the narrowest part of the CoA was measured during angiography and compared to the descending part of the aorta, close to the diaphragm. The intention was to reach the same diameter as the descending aorta, although this diameter was not always exactly measured. The length of the stent was chosen to cover the length of the anomaly, ranging from a short focal narrowing to (in rare cases) a longer diffuse aortic arch hypoplasia. With growing experience, it was attempted to cover the whole lesion from proximal to distal, thereby barely positioning the distal zigs against the wall to avoid later aneurysm formation. All implants were done under general anesthesia. The technical parameters (type and size of stent), hemodynamic parameters (peak-to-peak systolic gradient before and after stenting) and peri-procedural complications were recorded. Only 8-zig covered Cheatham Platinum (CCP) stents (Numed Inc., Hopkinton, NY, USA) were included in the study.

Blood pressure measurement and antihypertensive drugs

Blood pressure was measured by cuff sphygmomanometer on the right arm and left leg. No patients with an arteria lusoria were included and, as such, blood pressure was expected to be the highest in the right arm in all cases. Blood pressure in the lower limbs was mostly measured in the left leg and femoral pulsations were systemically examined. Only in-office

measurements were analyzed whereas ambulatory blood pressure measurements were not taken into account. When systemic hypertension was confirmed, medical treatment was started at the discretion of the treating physician. The numbers of antihypertensive medications prior to intervention and at each follow-up were systematically recorded.

Follow-up

Patients were followed after 1-3 months and thereafter every 6-12 months. Catheterization, computed tomography or magnetic resonance imaging was repeated only in case of suspected complications.

Statistical analysis

Continuous variables are presented as mean plus minus standard deviation (range minimum - maximum). In case of an asymmetric distribution of data, results are reported as median (interquartile range (IQR)). Proportions are noted as number and percentage. Comparison of individual parameters before and after stenting was performed using the two-tailed paired t test. Categorical data were compared with a McNemar. A p value of less than 0.05 was considered statistically significant. Statistical analysis was done using the SPSS software version 26 package (SPSS Inc., Chicago, IL USA).

Results

Characteristics of the study population

A total of 89 patients (mean age 23.9 ± 15.8 years of which 35 patients < 16 years and 54 patients ≥ 16 years, 67.4% male) underwent covered stent implantation. Table 1 summarizes the demographic data including the operative and/or interventional history and indications for stenting.

Peri-procedural results

At the initial catheterization, the mean diameter at the narrowest point of the coarctation prior to dilatation was 8 ± 3 (range 3 – 14) mm, corrected for body surface area 5 ± 2 (range 2 – 9) mm/m². The stent was inflated to a mean diameter of 16 ± 3 (range 10 – 30) mm, corrected for body surface area 10 ± 2 (range 6 – 20) mm/m². All implanted stents were covered Cheatham Platinum stents (CCP, Numed Inc., Hopkinton, NY, USA): 8z22 (1.1%), 8z28 (18.0%), 8z34 (25.8%), 8z39 (25.8%), 8z45 (28.1%) and 8z55 (1.1%).

Baseline invasive pressure measurements are shown in table 2. Overall, the mean ascending-descending pressure gradient across the coarctation decreased from 25 ± 16 mmHg to 4 ± 7 mmHg ($p < 0.001$). All procedures were successful without any malposition, migration or dissection.

In our clinical practice, patients are followed within a time window of less than 3 months after the intervention. As such, we present peri-procedural complications as complications < 3 months. This information was available for 88 of the 89 patients (98.9%). The peri-procedural complication rate was low (4.5%) and mostly due to vascular injuries at the access site: femoral artery pseudoaneurysm (n=1), access site bleeding (n=1) and femoral

artery occlusion for which an aorto-femoral bypass was necessary (n=1). Pulsations of the femoral arteries were systematically examined, and ultrasound examinations were only done when clinical suspicion of a femoral artery injury. As such, subclinical injuries were not reported. One patient developed pericarditis without any pericardial effusion on transthoracic echocardiography and AWI was excluded by computed tomography (CT) scan. Because of the radiation load, patients did not undergo systematically a CT scan within 3 months after the procedure; however, there were no clinically apparent AWIs. There were no strokes or deaths and no immediate re-interventions. Median length of hospital stay after stent implantation was 1 (range 1 – 5) day. Longer hospital stay was related to access site complications.

Longer-term follow-up

The mean systolic blood pressure (SBP) gradient between arm and leg before stent implantation was 38 ± 24 mmHg. There was a significant improvement of the mean SBP gradient at 3 months follow-up (10 ± 20 vs 38 ± 24 mmHg; $p < 0.001$). Data on blood pressure differences were available in 49 (55.1%) of the original 89 patients. At 1-year follow-up, there was a persistent decrease of the SBP gradient (10 ± 17 vs 38 ± 24 mmHg; $p < 0.001$), available in 58 (65.2%) of the patients. Finally, at latest follow-up, blood pressure (BP) measurements in upper and lower limbs could be retrieved from 56 patients (63.0%), where the SBP gradient was practically nonexistent, compared to pre-stent values (-7 ± 18 vs 38 ± 24 mmHg; $p < 0.001$). Mean follow-up time was 6.6 ± 3.7 years (min max range 0.2 – 15.7 years).

Systemic arterial hypertension and antihypertensive drugs

Mean systolic and diastolic BP, measured at the right arm before stent implantation was 150 ± 19 mmHg and 82 ± 13 mmHg respectively. Criteria for systemic hypertension ($> 140/90$ mmHg) were found in 70.8% of the patients. At three months follow-up, mean systolic and diastolic BP, available for 84 patients (94.4%) was 133 ± 16 mmHg and 72 ± 11 mmHg, respectively ($p < 0.001$ vs pre-stent, for both). The criteria for systemic hypertension were met in 27.4% of the cases. At one-year follow-up, with a systolic upper-to-lower BP gradient of 10 ± 17 mmHg, mean systolic and diastolic BP, available in 83 patients (93.3%), was 132 ± 19 mmHg and 71 ± 11 mmHg, respectively ($p < 0.001$ vs pre-stent, for both). The criteria for systemic hypertension were met in 22.9% of the patients. At latest follow-up, with a systolic upper-to-lower BP gradient of -7 ± 18 mmHg, mean systolic and diastolic BP, available in 88 patients (98.9%), was 134 ± 16 mmHg and 73 ± 12 mmHg respectively ($p < 0.001$ vs pre-stent, for both). At latest follow-up, 31.8% of the patients remained hypertensive. Data on SBP at different time points are plotted in figure 1.

Of the 30 patients receiving antihypertensive treatment before intervention, less medication could be applied in 13 patients (43.3%) after intervention. Of note, the first data on the use of antihypertensive treatment were collected 1 year after stenting. The proportion of patients who had hypertension but received no antihypertensive treatment before the stenting was 39.3% ($n = 35$). Of this proportion, 26 patients (74.3%) were normotensive at 3-months follow-up without any additional antihypertensive drug. Although blood pressures immediately after general anesthesia and the day after the stenting were systematically recorded, these measurements were not analyzed and considered too short after intervention to adapt already treatment.

At latest follow-up, 13 patients (50%) were diagnosed with hypertension, meaning that they received at least 1 antihypertensive drug (n = 9, 34.6%) or had a clinical diagnosis of hypertension (BP > 140/90 mmHg) but did not receive any treatment yet (n = 4, 15.4%). We did not have data on long-term follow-up in 1 patient (figure 2).

Overall, 30 of the 89 patients (33.7%) were on antihypertensive medication before intervention, of which 18 (20.2%) were receiving ≥ 2 medications to control BP. At latest follow-up, there were more patients on antihypertensive medication (42 of 84 patients (50%)), as well as a larger proportion (23 of 84 patients (27.4%)) requiring ≥ 2 antihypertensive drugs to control blood pressure ($p = 0.017$ and $p = 0.066$). Five patients were lost to follow-up. Proportions of patients with antihypertensive treatment before stenting and at latest follow-up are plotted in figure 1.

Adverse events and reintervention

Since the development of aortic aneurysms or pseudo-aneurysms is rarely clinical apparent, it is important to systematically survey for these adverse-advents during long-term follow-up. In our study, we didn't have any follow-up data regarding imaging in 14 of the 89 patients (15.7%). Of the remaining 75 patients, 47 patients (62.7%) had follow-up imaging within the *first five years of follow-up*. Different imaging modalities were used during follow-up: CT scan was performed in 18 patients (38.3%), cardiac magnetic resonance (CMR) in 13 patients (27.7%) and both CT and CMR in 4 patients (8.5%). A second angiography was performed in 12 patients (25.5%) that didn't have a CT or CMR during follow-up and reflected for a large part the expected reinterventions due to further dilatation to account

for somatic growth. Of the 28 patients that didn't have follow-up imaging within the first five years, 14 patients had a follow-up time of less than five years (figure 3).

During follow-up, long-term adverse events related to stent implantation were found in 4 patients (4.5%). Two patients had a covered stent fracture for which an additional stent was implanted. New aneurysms were observed in another 2 patients: one aneurysm was located at the proximal part of the covered stent and treated with a second covered stent. One patient experienced a stent fracture with rupture of the membrane causing a posteriorly located aneurysm, which could also be treated with a covered stent. Of note, in 22 patients (29,3%) no follow-up imaging was performed.

Expected aortic re-interventions for reCoA were performed in 24 patients (27.0%) with more than 1 intervention in 4 patients (4.5%) and 5 interventions (5.6%) within the year. These expected re-interventions reflected the practice of staged therapy for severe obstructions in the entire cohort and elective further dilatation of stents to account for somatic growth. Further dilatation of the existing stent in 22 patients and additional stents were implanted in 6. Of the 4 patients with more than 1 intervention, 2 patients had further dilatation at two different time points and 2 patients had further dilatation and additional stenting during longer follow-up. No acute AWIs have been noted in relation to these re-interventions.

Four patients died during follow-up. A 21-year old woman died 6 years after stent implantation due to a malignant melanoma. A 71-year old woman died 2 years after stent implantation because of septic shock, which was of respiratory origin. The cause of death of

a 59-year old man who died 2 years after stent implantation and a 48-year old man who died 4 years after stent implantation could not be retrieved from the patients' records.

Discussion

Covered stents are increasingly used in severe and complex coarctations of the aorta, mainly to avoid the risk of aortic wall injuries, such as local aneurysm formation, dissection and aortic rupture^{19-21,28-30}. Nevertheless, the aorta can still rupture with a covered stent, but no unlimited bleeding will occur, unless there was insufficient sealing, the covering was torn or in case of vessel tear with retrograde bleeding from collaterals. Most of the data on the use of covered stents in CoA is limited to immediate and intermediate outcome, whereas results on long-term outcome are sparse. In this retrospective study, patients were followed for a mean period of 6.6 ± 3.7 years (maximum follow-up time 15.7 years). To our knowledge, this is the largest study with the longest follow-up of the use of covered stents in (re)CoA.

In our study, covered stent implantation was highly effective for acute relief of an aortic obstruction, supporting prior reports in which stenting with a covered stent consistently reduced invasive measured gradients^{23,31}. The in-hospital rate of complications was low and exclusively due to access site vascular injuries. Relatively large sheaths are used (up to 14 Fr in the femoral artery) for these procedures. The easiness to puncture the femoral artery, the degree of temporarily prolonged anticoagulation immediately after removing the sheath, and the effectiveness of the local compression technique all play a substantial role in avoiding vascular complications. In our series the number of events was too low for a valid statistical analysis. Although there is concern of potential, clinically significant, occlusion of an aortic side branch³², this was not observed in our study. Furthermore, there were no aortic wall injuries, strokes or deaths, which further emphasizes the short-term safety of covered stent implantation in patients with CoA.

Although there is an improvement in systemic hypertension, the blood pressure profile is not normalized, and residual systemic arterial hypertension is a common complication after CoA repair. The prevalence varies between 25-45%^{4,33,34}. As a consequence, these patients remain to be exposed to increased cardiovascular risk with premature morbidity and mortality^{3,35}. Therefore, identifying elevated blood pressures is important for long-term follow-up.

In this study, patients had an excellent immediate hemodynamic effect after stenting, which persisted at 3-month follow-up with a permanent reduction of their mean blood pressure gradient compared to the pre-stent values. This beneficial result persisted also at one year and at long-term follow-up.

These results are in accordance with other studies, showing that the blood pressure profile can improve immediately and during mid- and long-term follow-up, after relieving the stenosis of the coarctation^{33,36-38}. However, in contrast to other studies using a covered stent to repair CoA^{19,23}, antihypertensive therapy could not be permanently reduced or discontinued in our series. We rather noticed an increase in antihypertensive drugs requirement to achieve rigorous BP control at later follow-up. One third of the patients was still hypertensive at latest follow-up. This number is probably overestimated because the blood pressures refer to in-office measurements. In case of elevated blood pressures in-office, the patient is instructed to measure the home blood pressure and to mail the results to the congenital heart disease team of the hospital. As such, it is confirmed that there is sometimes a discrepancy between in-office and ambulatory blood pressure recordings. Treatment is only adapted to achieve normal blood pressures at home (< 135/85 mmHg). Because of the retrospective design, ambulatory blood pressure measurements were not

systemically performed in all patients. Only when home blood pressure measurements were unreliable, ambulatory blood pressure measurements were performed. This occurred only in a minority of cases. Although most studies on covered stent implantation do not report exact percentages of patients with residual systemic hypertension, the percentage of short-term residual hypertension in our study was in line with the study of Sohrabi et al ²³. Also for longer-term hypertension, the percentage of patients with residual hypertension was comparable to the percentage mentioned in other studies ^{4,5,33,34}.

The fact that a significant number of patients with hypertension after CoA repair do not have residual obstruction, underlines the complexity of the pathophysiology of residual hypertension. The latter has been linked to several mechanisms, including abnormal geometry of the aortic arch, changes in arterial function, attenuation of baroreflexes or hyperactivation of the renin angiotensin system ^{33,38-43}. As such, lifelong follow-up of these patients remains mandatory. An open vessel does not equal a normal blood pressure. Despite early and successful anatomic repair, patients with CoA may still develop aneurysm formation during long-term follow-up due to the associated abnormal vascular phenotype. Also therefore, lifelong follow-up with routine imaging surveillance should be performed in these patients, even when asymptomatic.

Long-term adverse events due to stent implantation was seen in 4 patients (stent fracture and aneurysm formation). Although no previous reports have been issued specifically on aneurysm formation after covered stent placement and the interpretation of data is confounded by mostly heterogeneous subject populations and incomplete follow-up, a covered stent might protect the post-stenotic area by diverging the flow from the dilated areas and more centrally into the descending aortic lumen. This favorable hemodynamic

effect could explain the lack of aneurysm formation during the first years of follow-up.

However, since we did not perform routine imaging late after stenting, we cannot compare our results with the existing literature on bare stents.

Limited data are available on the usefulness of covered stents in preventing reCoA⁴⁴.

Although aortic reinterventions were common in our study (31.5%), and notably higher than in most surgical series, this reflected for the most part our initial practice of staged therapy for severe obstructions in children and adults. A higher number of reinterventions reflects elective further dilatation of stents to account for somatic growth in children. Regardless of the indication, reintervention seemed in general efficient and safe with no immediate or long-term procedural complications. The latter demonstrates the relative ease in re-dilating these covered stents.

There were 4 deaths in our series during follow-up. None of them, however, could be linked directly to the covered stent implantation.

Study limitations:

Our study has some limitations. The most important limitation is the retrospective, single-center design and the incomplete follow-up achieved. We acknowledge that especially follow-up data on SBP gradients between right arm and leg was incomplete. Furthermore, because our study only included patients with covered stents, we cannot compare our results regarding short- and long-term complications and blood pressure regulation to other endovascular or surgical options in the management of CoA. Patient groups would have no similar baseline characteristics and as a consequence difficult to compare. Patients did not

undergo 24h blood pressure measurements, which could have studied the normotensive state more accurately. Also, blood pressure response during exercise testing could have been more valuable to define procedure outcome. We did not present BP data as Z-values in the young population and, as such, we may have underestimated hypertension in a proportion of these young patients. Since data on follow-up imaging was incomplete, we cannot exclude that the rate of adverse events was higher than described in our study. Finally, the ultimate goal of these procedures is to prolong survival without vascular complications in patients with CoA. Only long-term follow-up will determine whether this objective will be met.

Conclusion:

The main findings of this study show that covered stent implantation in patients with severe coarctation of the aorta is highly successful, safe and results in permanent positive hemodynamic effects during long term follow-up.

However, to achieve these long-term results, many patients require additional drug treatment to control blood pressure and as such a lifelong follow-up of these patients, encompasses a rigorous control of cardiovascular risk factors.

Acknowledgments

Not applicable.

References

1. Hoffman JI, Kaplan S. The incidence of congenital heart disease. *J Am Coll Cardiol* 2002;39(12):1890-900. (In eng). DOI: 10.1016/s0735-1097(02)01886-7.
2. Campbell M. Natural history of coarctation of the aorta. *Br Heart J* 1970;32(5):633-40. (In eng). DOI: 10.1136/hrt.32.5.633.
3. Cohen M, Fuster V, Steele PM, Driscoll D, McGoon DC. Coarctation of the aorta. Long-term follow-up and prediction of outcome after surgical correction. *Circulation* 1989;80(4):840-5. (In eng). DOI: 10.1161/01.cir.80.4.840.
4. Stewart AB, Ahmed R, Travill CM, Newman CG. Coarctation of the aorta life and health 20-44 years after surgical repair. *Br Heart J* 1993;69(1):65-70. (In eng). DOI: 10.1136/hrt.69.1.65.
5. Brown ML, Burkhart HM, Connolly HM, et al. Coarctation of the aorta: lifelong surveillance is mandatory following surgical repair. *J Am Coll Cardiol* 2013;62(11):1020-5. (In eng). DOI: 10.1016/j.jacc.2013.06.016.
6. Verheugt CL, Uiterwaal CS, Grobbee DE, Mulder BJ. Long-term prognosis of congenital heart defects: a systematic review. *Int J Cardiol* 2008;131(1):25-32. (In eng). DOI: 10.1016/j.ijcard.2008.06.023.
7. Hager A, Kanz S, Kaemmerer H, Schreiber C, Hess J. Coarctation Long-term Assessment (COALA): significance of arterial hypertension in a cohort of 404 patients up to 27 years after surgical repair of isolated coarctation of the aorta, even in the absence of restenosis and prosthetic material. *J Thorac Cardiovasc Surg* 2007;134(3):738-45. (In eng). DOI: 10.1016/j.jtcvs.2007.04.027.
8. Wheatley GH, Koullias GJ, Rodriguez-Lopez JA, Ramaiah VG, Diethrich EB. Is endovascular repair the new gold standard for primary adult coarctation? *Eur J Cardiothorac Surg* 2010;38(3):305-10. (In eng). DOI: 10.1016/j.ejcts.2010.02.003.
9. Hu ZP, Wang ZW, Dai XF, et al. Outcomes of surgical versus balloon angioplasty treatment for native coarctation of the aorta: a meta-analysis. *Ann Vasc Surg* 2014;28(2):394-403. (In eng). DOI: 10.1016/j.avsg.2013.02.026.
10. Mahadevan V, Mullen MJ. Endovascular management of aortic coarctation. *Int J Cardiol* 2004;97 Suppl 1:75-8. (In eng). DOI: 10.1016/j.ijcard.2004.08.011.
11. Qureshi AM, McElhinney DB, Lock JE, Landzberg MJ, Lang P, Marshall AC. Acute and intermediate outcomes, and evaluation of injury to the aortic wall, as based on 15 years experience of implanting stents to treat aortic coarctation. *Cardiol Young* 2007;17(3):307-18. (In eng). DOI: 10.1017/S1047951107000339.
12. Chessa M, Carrozza M, Butera G, et al. Results and mid-long-term follow-up of stent implantation for native and recurrent coarctation of the aorta. *Eur Heart J* 2005;26(24):2728-32. (In eng). DOI: 10.1093/eurheartj/ehi491.
13. Rosenthal E. Stent implantation for aortic coarctation: the treatment of choice in adults? *J Am Coll Cardiol* 2001;38(5):1524-7. (In eng). DOI: 10.1016/s0735-1097(01)01573-x.
14. Forbes TJ, Kim DW, Du W, et al. Comparison of surgical, stent, and balloon angioplasty treatment of native coarctation of the aorta: an observational study by the CCISC (Congenital Cardiovascular Interventional Study Consortium). *J Am Coll Cardiol* 2011;58(25):2664-74. (In eng). DOI: 10.1016/j.jacc.2011.08.053.

15. Pedra CA, Fontes VF, Esteves CA, et al. Stenting vs. balloon angioplasty for discrete unoperated coarctation of the aorta in adolescents and adults. *Catheter Cardiovasc Interv* 2005;64(4):495-506. (In eng). DOI: 10.1002/ccd.20311.
16. Butera G, Manica JL, Marini D, et al. From bare to covered: 15-year single center experience and follow-up in trans-catheter stent implantation for aortic coarctation. *Catheter Cardiovasc Interv* 2014;83(6):953-63. (In eng). DOI: 10.1002/ccd.25404.
17. Diethrich EB, Heuser RR, Cardenas JR, Eckert J, Tarlian H. Endovascular techniques in adult aortic coarctation: the use of stents for native and recurrent coarctation repair. *J Endovasc Surg* 1995;2(2):183-8. (In eng). DOI: 10.1583/1074-6218(1995)0022.0.CO;2.
18. Cheatham JP. Stenting of coarctation of the aorta. *Catheter Cardiovasc Interv* 2001;54(1):112-25. (In eng). DOI: 10.1002/ccd.1249.
19. Tzifa A, Ewert P, Brzezinska-Rajszyz G, et al. Covered Cheatham-platinum stents for aortic coarctation: early and intermediate-term results. *J Am Coll Cardiol* 2006;47(7):1457-63. (In eng). DOI: 10.1016/j.jacc.2005.11.061.
20. Qureshi SA, Zubrzycka M, Brzezinska-Rajszyz G, Kosciesza A, Ksiazek J. Use of covered Cheatham-Platinum stents in aortic coarctation and recoarctation. *Cardiol Young* 2004;14(1):50-4. (In eng). DOI: 10.1017/s104795110400109x.
21. Butera G, Piazza L, Chessa M, et al. Covered stents in patients with complex aortic coarctations. *Am Heart J* 2007;154(4):795-800. (In eng). DOI: 10.1016/j.ahj.2007.06.018.
22. Butera G, Dua J, Chessa M, Carminati M. Covered Cheatham-Platinum stents for serial dilatation of severe native aortic coarctation. *Catheter Cardiovasc Interv* 2010;75(3):472; author reply 473. (In eng). DOI: 10.1002/ccd.22281.
23. Sohrabi B, Jamshidi P, Yaghoubi A, et al. Comparison between covered and bare Cheatham-Platinum stents for endovascular treatment of patients with native post-ductal aortic coarctation: immediate and intermediate-term results. *JACC Cardiovasc Interv* 2014;7(4):416-23. (In eng). DOI: 10.1016/j.jcin.2013.11.018.
24. Baumgartner H, Bonhoeffer P, De Groot NM, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). *Eur Heart J* 2010;31(23):2915-57. (In eng). DOI: 10.1093/eurheartj/ehq249.
25. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J* 2018;39(33):3021-3104. (In eng). DOI: 10.1093/eurheartj/ehy339.
26. Poirier NC, Van Arsdell GS, Brindle M, et al. Surgical treatment of aortic arch hypoplasia in infants and children with biventricular hearts. *Ann Thorac Surg* 1999;68(6):2293-7. (In eng). DOI: 10.1016/s0003-4975(99)01144-3.
27. Gewillig M, Boshoff D, Budts W. Catheter-Based Interventions of the Aorta. In: Da Cruz E. ID, Jaggers J., ed. *Pediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care*. London: Springer; 2014:1101-1125.
28. de Giovanni JV. Covered stents in the treatment of aortic coarctation. *J Interv Cardiol* 2001;14(2):187-90. (In eng). DOI: 10.1111/j.1540-8183.2001.tb00732.x.
29. Tanous D, Collins N, Dehghani P, Benson LN, Horlick EM. Covered stents in the management of coarctation of the aorta in the adult: initial results and 1-year angiographic and hemodynamic follow-up. *Int J Cardiol* 2010;140(3):287-95. (In eng). DOI: 10.1016/j.ijcard.2008.11.085.

30. Kenny D, Margey R, Turner MS, Tometzki AJ, Walsh KP, Martin RP. Self-expanding and balloon expandable covered stents in the treatment of aortic coarctation with or without aneurysm formation. *Catheter Cardiovasc Interv* 2008;72(1):65-71. (In eng). DOI: 10.1002/ccd.21559.
31. Taggart NW, Minahan M, Cabalka AK, et al. Immediate Outcomes of Covered Stent Placement for Treatment or Prevention of Aortic Wall Injury Associated With Coarctation of the Aorta (COAST II). *JACC Cardiovasc Interv* 2016;9(5):484-93. (In eng). DOI: 10.1016/j.jcin.2015.11.038.
32. Sadiq M, Ur Rehman A, Qureshi AU, Qureshi SA. Covered stents in the management of native coarctation of the aorta--intermediate and long-term follow-up. *Catheter Cardiovasc Interv* 2013;82(4):511-8. (In eng). DOI: 10.1002/ccd.24945.
33. Ou P, Bonnet D, Auriacombe L, et al. Late systemic hypertension and aortic arch geometry after successful repair of coarctation of the aorta. *Eur Heart J* 2004;25(20):1853-9. (In eng). DOI: 10.1016/j.ehj.2004.07.021.
34. Quennelle S, Powell AJ, Geva T, Prakash A. Persistent Aortic Arch Hypoplasia After Coarctation Treatment Is Associated With Late Systemic Hypertension. *J Am Heart Assoc* 2015;4(7) (In eng). DOI: 10.1161/JAHA.115.001978.
35. Clarkson PM, Nicholson MR, Barratt-Boyes BG, Neutze JM, Whitlock RM. Results after repair of coarctation of the aorta beyond infancy: a 10 to 28 year follow-up with particular reference to late systemic hypertension. *Am J Cardiol* 1983;51(9):1481-8. (In eng). DOI: 10.1016/0002-9149(83)90661-6.
36. Smith Maia MM, Cortês TM, Parga JR, et al. Evolutional aspects of children and adolescents with surgically corrected aortic coarctation: clinical, echocardiographic, and magnetic resonance image analysis of 113 patients. *J Thorac Cardiovasc Surg* 2004;127(3):712-20. (In eng). DOI: 10.1016/s0022-5223(03)01018-3.
37. de Divitiis M, Pilla C, Kattenhorn M, et al. Ambulatory blood pressure, left ventricular mass, and conduit artery function late after successful repair of coarctation of the aorta. *J Am Coll Cardiol* 2003;41(12):2259-65. (In eng). DOI: 10.1016/s0735-1097(03)00480-7.
38. De Caro E, Trocchio G, Smeraldi A, Calevo MG, Pongiglione G. Aortic arch geometry and exercise-induced hypertension in aortic coarctation. *Am J Cardiol* 2007;99(9):1284-7. (In eng). DOI: 10.1016/j.amjcard.2006.12.049.
39. Brili S, Tousoulis D, Antoniadis C, et al. Evidence of vascular dysfunction in young patients with successfully repaired coarctation of aorta. *Atherosclerosis* 2005;182(1):97-103. (In eng). DOI: 10.1016/j.atherosclerosis.2005.01.030.
40. Menon A, Eddinger TJ, Wang H, Wendell DC, Toth JM, LaDisa JF. Altered hemodynamics, endothelial function, and protein expression occur with aortic coarctation and persist after repair. *Am J Physiol Heart Circ Physiol* 2012;303(11):H1304-18. (In eng). DOI: 10.1152/ajpheart.00420.2012.
41. Parker FB, Streeten DH, Farrell B, Blackman MS, Sondheimer HM, Anderson GH. Preoperative and postoperative renin levels in coarctation of the aorta. *Circulation* 1982;66(3):513-4. (In eng). DOI: 10.1161/01.cir.66.3.513.
42. Iglar FO, Boerboom LE, Werner PH, et al. Coarctation of the aorta and baroreceptor resetting. A study of carotid baroreceptor stimulus-response characteristics before and after surgical repair in the dog. *Circ Res* 1981;48(3):365-71. (In eng). DOI: 10.1161/01.res.48.3.365.

43. Johnson D, Perrault H, Vobecky SJ, et al. Resetting of the cardiopulmonary baroreflex 10 years after surgical repair of coarctation of the aorta. *Heart* 2001;85(3):318-25. (In eng). DOI: 10.1136/heart.85.3.318.
44. Butera G, Gaio G, Carminati M. Redilation of e-PTFE covered CP stents. *Catheter Cardiovasc Interv* 2008;72(2):273-7. (In eng). DOI: 10.1002/ccd.21609.

Figure 1. Central illustration. Change in blood pressure and proportion of coarctation patients with antihypertensive treatment. Decrease in systolic blood pressure after stenting persists during follow-up (values are mean $\pm$ SD), but the proportion of patients needing antihypertensive treatment increases over time (values are percentages). SBP = systolic blood pressure. * Paired t test and ** McNemar test.

Figure 2. Evolution of number of patients with systemic hypertension without treatment before stent implantation. Twenty-six of 35 patients became normotensive 3 months after stenting. At latest follow-up 50% of these 26 patients needed anti-hypertensive treatment.

Figure 3. Imaging the aorta at 5 years follow-up.

Table 1 Baseline patient demographics

	Entire cohort (n.89)
Sex	
Male	60 (67.4)
Female	29 (32.6)
Age, yrs	23.9 ± 15.8 (5.1–71.6)
<16 years	35 (39.3)
≥16 years	54 (60.7)
Weight, kg	61.8 ± 18.2 (18.0–102.0)
Length, cm	165.4 ± 16.8 (113.0–194.0)
BSA, m ²	1.7 ± 0.3 (0.8–2.3)
Associated congenital anomaly	55 (61.8)
Bicuspid aortic valve	30 (33.7)
Asymmetric tricuspid aortic valve	20 (22.5)
Ventricular septal defect	7 (7.9)
Location of CoA	
Isthmus	85 (95.5)
Arcus transversus	4 (4.5)
Prior aortic interventions	32 (36.0)
Surgical intervention	13 (14.6)
Coarctectomy	11 (12.4)
Root replacement with AV implantation	2 (2.2)
Transcatheter intervention	10 (11.2)
Balloon angioplasty	8 (9.0)
Bare stent placement	2 (2.2)
Combined intervention	9 (10.1)
Coarctectomy and balloon dilatation	8 (9.0)
Coarctectomy and bare stent placement	1 (1.1)
Indication for stenting	
Hypertension with peak-to-peak gradient ≥20 mmHg	35 (39.3)
Hypertension with peak-to-peak gradient <20 mmHg but ≥50% narrowing of the aorta	23 (25.8)
No hypertension with peak to peak ≥20 mmHg	13 (14.6)
No hypertension with peak to peak <20 mmHg but ≥50% narrowing of the aorta	11 (12.4)
No information available	7 (7.9)

Values are n (%) or mean ± SD (minimum–maximum). AV: aortic valve; BSA: body surface area; CoA: coarctation of the aorta.

Table 2 Invasive hemodynamic measures pre-/post stent implantation

	Pre	Post	p Value
AAo SBP, mmHg	107 ± 22	106 ± 22	0.932
AAo DBP, mmHg	60 ± 14	63 ± 12	0.040
DAo SBP, mmHg	82 ± 17	102 ± 22	<0.001
DAo DBP, mmHg	59 ± 12	63 ± 12	0.001
SPG AAO – Dao, mmHg	25 ± 16	4 ± 7	<0.001

Values are mean ± SD. AAO: ascending aorta; Dao: descending aorta; SBP: systolic blood pressure; DBP: diastolic blood pressure; SPG: systolic pressure gradient.